CR8904A - Formulaciones estabilizadoras - Google Patents

Formulaciones estabilizadoras

Info

Publication number
CR8904A
CR8904A CR8904A CR8904A CR8904A CR 8904 A CR8904 A CR 8904A CR 8904 A CR8904 A CR 8904A CR 8904 A CR8904 A CR 8904A CR 8904 A CR8904 A CR 8904A
Authority
CR
Costa Rica
Prior art keywords
protein
storing
methods
relatively low
formulation
Prior art date
Application number
CR8904A
Other languages
English (en)
Spanish (es)
Inventor
Li Li
Angela Kantor
Shannon B Macmillan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8904A publication Critical patent/CR8904A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CR8904A 2004-08-13 2007-02-06 Formulaciones estabilizadoras CR8904A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60131104P 2004-08-13 2004-08-13

Publications (1)

Publication Number Publication Date
CR8904A true CR8904A (es) 2007-08-28

Family

ID=35908214

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8904A CR8904A (es) 2004-08-13 2007-02-06 Formulaciones estabilizadoras

Country Status (18)

Country Link
US (1) US8871201B2 (enExample)
EP (1) EP1784219B1 (enExample)
JP (1) JP4948407B2 (enExample)
KR (1) KR20070092197A (enExample)
CN (1) CN101022831A (enExample)
AR (1) AR051009A1 (enExample)
AU (1) AU2005272603A1 (enExample)
BR (1) BRPI0514340A (enExample)
CA (1) CA2575870A1 (enExample)
CR (1) CR8904A (enExample)
EC (1) ECSP077246A (enExample)
ES (1) ES2637854T3 (enExample)
IL (1) IL181265A0 (enExample)
MX (1) MX2007001599A (enExample)
NO (1) NO20070930L (enExample)
RU (1) RU2007109062A (enExample)
TW (1) TW200621282A (enExample)
WO (1) WO2006020935A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
KR101317235B1 (ko) * 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
US20080070230A1 (en) * 2006-06-12 2008-03-20 Wyeth Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions
EP1950225A1 (de) * 2007-01-25 2008-07-30 Octapharma AG Verfahren zur Steigerung von Proteinausbeuten
KR20100014674A (ko) 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
NZ585702A (en) * 2007-11-30 2013-08-30 Abbott Lab Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
CA2840711C (en) * 2011-07-01 2023-10-17 Biogen Idec Ma Inc. Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use
WO2013082427A1 (en) 2011-11-30 2013-06-06 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP3431104A1 (en) * 2012-03-26 2019-01-23 Sanofi Stable igg4 binding agent formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9844594B2 (en) * 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
PT3834824T (pt) 2014-03-28 2025-11-18 Univ Duke Tratamento do cancro da mama positivo para o receptor de estrogénio utilizando um modulador seletivo do recetor de estrogénio
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
CN107076759A (zh) * 2014-07-21 2017-08-18 非链实验室 从δg的浓度依赖性来测定蛋白质聚集
CA2984357A1 (en) 2015-04-29 2016-11-03 Radius Pharmaceuticals, Inc. Methods for treating cancer
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
HUE052805T2 (hu) 2016-08-18 2021-05-28 Regeneron Pharma Fehérje önasszociációs képességének meghatározására szolgáló assay koncentrációfüggõ öninterakciós nanorészecske-spektroszkópia segítségével
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
MX383786B (es) 2017-01-05 2025-03-14 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
AU2019297421B2 (en) 2018-07-04 2024-08-29 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD 1901-2HCL
MX2021009569A (es) 2019-02-12 2021-09-08 Radius Pharmaceuticals Inc Procesos y compuestos.
EP4142792A4 (en) * 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein
WO2022154529A1 (ko) * 2021-01-14 2022-07-21 한올바이오파마주식회사 안정화제를 사용하지 않고도 안정한, 탄파너셉트를 포함하는 안과용 조성물
CN115541895B (zh) * 2022-11-29 2023-05-19 天津德祥生物技术股份有限公司 一种提高微流控反定检测卡灵敏度的配方液及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3176517D1 (en) 1980-04-24 1987-12-17 Beecham Group Plc Beta-lactam compounds, their preparation and use
GB8518416D0 (en) 1985-07-22 1985-08-29 Beecham Group Plc Compounds
US5869053A (en) * 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6852703B1 (en) 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
WO1999037329A1 (en) 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
ES2477996T3 (es) * 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
ATE442862T2 (de) * 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
WO2003057163A2 (en) * 2002-01-03 2003-07-17 Smithkline Beecham Corporation Methods for preparing immunoconjugates
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CA2535804A1 (en) * 2003-08-14 2005-03-03 Wyeth Anti-lewis y anti-idiotypic antibodies and uses thereof
BRPI0515113A (pt) 2004-09-10 2008-07-01 Wyeth Corp anticorpos anti-5t4 humanizados e conjugados de anticorpo anti-5t4/caliqueamicina

Also Published As

Publication number Publication date
IL181265A0 (en) 2007-07-04
TW200621282A (en) 2006-07-01
WO2006020935A2 (en) 2006-02-23
ES2637854T3 (es) 2017-10-17
JP4948407B2 (ja) 2012-06-06
US8871201B2 (en) 2014-10-28
MX2007001599A (es) 2007-04-10
ECSP077246A (es) 2007-05-30
AU2005272603A1 (en) 2006-02-23
KR20070092197A (ko) 2007-09-12
AR051009A1 (es) 2006-12-13
US20060115472A1 (en) 2006-06-01
CA2575870A1 (en) 2006-02-23
EP1784219A4 (en) 2010-02-17
EP1784219B1 (en) 2017-05-17
EP1784219A2 (en) 2007-05-16
BRPI0514340A (pt) 2008-06-10
RU2007109062A (ru) 2008-09-20
JP2008515775A (ja) 2008-05-15
WO2006020935A3 (en) 2007-03-08
NO20070930L (no) 2007-05-14
CN101022831A (zh) 2007-08-22

Similar Documents

Publication Publication Date Title
CR8904A (es) Formulaciones estabilizadoras
CR10290A (es) Metodos para reducir la aglomeracion de proteina
CY1121461T1 (el) Συνθεσεις που περιλαμβανουν δυσδιαλυτους στο νερο φαρμακευτικους παραγοντες και αντιμικροβιακους παραγοντες
TR201905081T4 (tr) Protein içeren formülasyonların stabilizasyonu için yararlı bileşimler ve yöntemler.
CR9620A (es) Composicion agricola
MX2009006594A (es) Formulaciones de ph regulado y estables que contienen polipeptidos.
ECSP088962A (es) Nuevos herbicidas
PE20120342A1 (es) Formulacion de anticuerpo
AR084285A1 (es) Composiciones inmunogenicas
MX2010008416A (es) Composiciones antimicrobianas y metodos de uso de las mismas.
CL2011000255A1 (es) Composicion liquida que comprende una proteina o polipeptido harpin, un portador acuoso, un agente biocida y opcionalmente un inhibidor de proteasa y surfactante no ionico; metodo para preparar dicha composicion; y metodo para inducir respuesta en una planta por aplicacion de dicha composicion.
CO6382079A2 (es) Composiciones insecticidas estables a base de sulfoximina
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
PE20070723A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
PE20091783A1 (es) Anticuerpos anti-factor d humanizados
BR112015022210A8 (pt) formulações de anticorpo
ES2570599T3 (es) Composición suave para desinfección cutánea
PE20110642A1 (es) Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso
AR086473A1 (es) Variantes de fitasa sintetica
PE20070437A1 (es) FORMULACION ACUOSA hFSH
CL2011001306A1 (es) Composicion antimicrobiana que comprende una sal de plata soluble, una alcanolamida, y/o aminoalcohol, un ph 6 o superior; composicion limpiadora que comprende un surfactante, una sal de plata soluble, una alcanolamida, y/o aminoalcohol.
AR118536A1 (es) Composiciones y métodos para estabilizar formulaciones que contienen proteína
AR086033A1 (es) Variantes de fitasa sintetica derivada de hafnia sp.
AR077384A1 (es) Una formulacion farmaceutica inyectable de melfalano.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)